What is the “best intro”—explanatory versus pragmatic antipsychotic drug trials

Stefan Leucht, John M. Davis

Publikation: Beitrag in Fachzeitschrift › Kommentar/Debatte

4 Zitate (Scopus)

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

@article{995723702cd04e7fbe28abcdd675bb4e,

title = "What is the “best intro”—explanatory versus pragmatic antipsychotic drug trials",

author = "Stefan Leucht and Davis, {John M.}",

year = "2020",

month = dec,

doi = "10.1016/S2215-0366(20)30436-3",

language = "English",

volume = "7",

pages = "1004--1006",

journal = "The Lancet Psychiatry",

issn = "2215-0366",

publisher = "Elsevier Ltd.",

number = "12",

}

TY - JOUR

T1 - What is the “best intro”—explanatory versus pragmatic antipsychotic drug trials

AU - Leucht, Stefan

AU - Davis, John M.

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85095413790&partnerID=8YFLogxK

U2 - 10.1016/S2215-0366(20)30436-3

DO - 10.1016/S2215-0366(20)30436-3

M3 - Comment/debate

C2 - 33069272

AN - SCOPUS:85095413790

SN - 2215-0366

VL - 7

SP - 1004

EP - 1006

JO - The Lancet Psychiatry

JF - The Lancet Psychiatry

IS - 12

ER -